Sugi Predict

Sugi Predict / Compounds / SCHEMBL352610

SCHEMBL352610

SCHEMBL352610

CC(C)(C)OC(=O)NCCC(N)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.63
▸ GAA P10253 1/20 0.63
▸ KMT2A Q03164 1/20 0.63
▸ TDP1 Q9NUW8 1/20 0.49
▸ MAOA P21397 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ CA12 O43570 5/20 0.41
▸ CA1 P00915 5/20 0.41
▸ CA2 P00918 5/20 0.41
▸ CA9 Q16790 5/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ CTSS P25774 1/20 0.39
▸ CTSK P43235 1/20 0.39
▸ SLC1A3 P43003 2/20 0.39
▸ SLC1A1 P43005 2/20 0.39
▸ MALT1 Q9UDY8 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ GRM8 O00222 1/20 0.38
▸ GRM6 O15303 1/20 0.38
▸ GRIN2D O15399 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3916161 1.00 MEN1 (0.63) MEN1GAAKMT2ATDP1MAOA
SCHEMBL18394313 1.00 MEN1 (0.63) MEN1GAAKMT2ATDP1MAOA
Hydrochloric Acid SCHEMBL4433195 0.98 MEN1 (0.61) MEN1GAAKMT2ATDP1MAOA
SCHEMBL12463276 0.90 MEN1 (0.73) MEN1GAAKMT2ATDP1MAOA
SCHEMBL12395380 0.90 MEN1 (0.73) MEN1GAAKMT2ATDP1MAOA
SCHEMBL7195305 0.90 MEN1 (0.73) MEN1GAAKMT2ATDP1MAOA
SCHEMBL4759987 0.89 MEN1 (0.68) MEN1GAAKMT2ATDP1MAOA
Hydrochloric Acid SCHEMBL25167231 0.89 MEN1 (0.71) MEN1GAAKMT2ATDP1MAOA
SCHEMBL3603914 0.89 MEN1 (0.67) MEN1GAAKMT2ATDP1MAOA
Hydrochloric Acid SCHEMBL4989741 0.89 MEN1 (0.71) MEN1GAAKMT2ATDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108290912-B Phosphinic acid peptide derivatives useful as MMP-12 inhibitors 帝斯曼知识产权资产管理有限公司 2021-02-05 — — CN claimed
EP-3383881-B1 PHOSPHINIC PEPTIDE DERIVATIVES FOR USE AS MMP-12 INHIBITORS DSM IP ASSETS BV (NL) 2019-07-31 — — EP claimed
US-10179797-B2 Phosphinic peptide derivatives for use as MMP-12 inhibitors DSM IP ASSETS B.V. (NL) 2019-01-15 — — US claimed
US-20180319829-A1 PHOSPHINIC PEPTIDE DERIVATIVES FOR USE AS MMP-12 INHIBITORS DSM IP ASSETS B.V. (NL) 2018-11-08 — — US claimed
EP-3383881-A1 PHOSPHINIC PEPTIDE DERIVATIVES FOR USE AS MMP-12 INHIBITORS DSM IP Assets B.V. (NL) 2018-10-10 — — EP claimed
WO-2017093093-A1 PHOSPHINIC PEPTIDE DERIVATIVES FOR USE AS MMP-12 INHIBITORS DSM IP ASSETS B.V. (NL) 2017-06-08 — — WO claimed
US-12605451-B2 Targeted plasma protein degradation NOVARTIS AG (CH) 2026-04-21 — — US disclosed
EP-4698275-A1 PYRROLIDINONE UREA FPR2 AGONISTS Bristol-Myers Squibb Company (US) 2026-02-25 — — EP disclosed
EP-4698516-A1 PYRROLIDINONE UREA FPR2 AGONISTS Bristol-Myers Squibb Company (US) 2026-02-25 — — EP disclosed
US-12173018-B2 Penicillin-binding protein inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2024-12-24 — — US disclosed
WO-2024220453-A1 PYRROLIDINONE UREA FPR2 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-10-24 — — WO disclosed
WO-2024220482-A1 PYRROLIDINONE UREA FPR2 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-10-24 — — WO disclosed
CN-114805365-B Factor XIA new macrocycles carrying non-aromatic P2' groups 百时美施贵宝公司 2024-07-23 — — CN disclosed
CN-101506213-A Amino-imidazolones and their use as medicaments for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia ASTRAZENECA AB (SE) 2009-08-12 — — CN disclosed
CN-101501041-A Amino-imidazolones and their use as medicaments for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia ASTRAZENECA AB (SE) 2009-08-05 — — CN disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 — — US disclosed
EP-1085870-A2 MULTIVALENT AGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF THE GABA RECEPTORS Advanced Medicine, Inc. (US) 2001-03-28 — — EP disclosed
WO-2001000656-A2 NOVEL INDAZOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-01-04 — — WO disclosed
WO-1999063933-A9 MULTIVALENT AGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF THE GABA RECEPTORS ADVANCED MEDICINE INC (US) 2000-04-27 — — WO disclosed
WO-1999063933-A2 MULTIVALENT AGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF THE GABA RECEPTORS ADVANCED MEDICINE, INC. (US) 1999-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180319829-A1 PHOSPHINIC PEPTIDE DERIVATIVES FOR USE AS MMP-12 INHIBITORS MMP12, MMP13, MMP11 MEN1 546/4885GAA 439/4885KMT2A 2328/4885
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE ROCK1, ROCK2, RHOA MEN1 2513/4885GAA 2235/4885KMT2A 3700/4885
US-12173018-B2 Penicillin-binding protein inhibitors PEPD, BPGM, EBPL MEN1 3629/4885GAA 345/4885KMT2A 2536/4885
US-12605451-B2 Targeted plasma protein degradation M6PR, ASGR1, IGF2R MEN1 1171/4885GAA 230/4885KMT2A 2504/4885
US-10179797-B2 Phosphinic peptide derivatives for use as MMP-12 inhibitors MMP12, MMP13, MMP11 MEN1 546/4885GAA 439/4885KMT2A 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.